Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis

Molecular Therapy

Volumn 8, Issue 6, 2003, Pages 886-894

  Jerusalmi, Alan ^a   Morris Downes, Margaret M ^a   Sheahan, Brian J ^b   Atkins, Gregory J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Central nervous system therapy; Cytokine therapy; Experimental autoimmune encephalomyelitis; IL 10; Intranasal delivery; Semliki forest virus vector

Indexed keywords

GREEN FLUORESCENT PROTEIN; INTERLEUKIN 10; VIRUS RNA; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG RESPONSE; FEASIBILITY STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION SYSTEM; MOUSE; NERVE FIBER; NONHUMAN; OLFACTORY BULB; OLFACTORY EPITHELIUM; PROTEIN LOCALIZATION; REPORTER GENE; SEMLIKI FOREST ALPHAVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS PARTICLE; VIRUS RECOMBINANT;

ALPHAVIRUS; ANIMALIA; RABBIT FIBROMA VIRUS; RNA VIRUSES; SEMLIKI FOREST VIRUS;

EID: 0346025622     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.09.010     Document Type: Article

References (45)

1. Atkins, G. J., Sheahan, B. J., and Liljestrom, P. (1999). The molecular pathogenesis of Semliki Forest virus: a model virus made useful? J. Gen. Virol. 80: 2287-2297.
2. Lundstrom, K. (2003). Semliki Forest virus vectors for gene therapy. Expert Opin. Biol. Ther. 3: 771-777.
3. Atkins, G. J., Sheahan, B. J., and Dimmock, N. J. (1985). Semliki Forest virus infection of mice: a model for genetic and molecular analysis of viral pathogenicity. J. Gen. Virol. 66: 395-408.
4. Atkins, G. J., et al. (1994). Analysis of the molecular basis of neuropathogenesis of RNA viruses in experimental animals: relevance for human disease? Neuropathol. Appl. Neurobiol. 20: 91-102.
5. Sammin, D. J., Butler, D., Atkins, G. J., and Sheahan, B. J. (1999). Cell death mechanisms in the olfactory bulb of rats infected intranasally with Semliki Forest virus. Neuropathol. Appl. Neurobiol. 25: 236-243.
6. Sheahan, B. J., Ibrahim, M. A., and Atkins, G. J. (1996). Demyelination of olfactory pathways in mice following intranasal infection with the avirulent A7 strain of Semliki Forest virus. Eur. J. Vet. Pathol. 2: 117-125.
7. Vaha-Koskela, M. J., et al. (2003). A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J. Neurovirol. 9: 1-15.
8. Morris-Downes, M. M., et al. (2001). Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19: 1978-1988.
9. Ehrengruber, M. U., et al. (1999). Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures. Proc. Natl. Acad. Sci. USA 96: 7041-7046.
10. Atkins, G. J., Sheahan, B. J., and Liljeström, P. (1996). Manipulation of the Semliki Forest virus genome and its potential for vaccine construction. Mol. Biotechnol. 5: 33-38.
11. Berglund, P., et al. (1993). Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Bio/Technology 11: 916-920.
12. Liljeström, P., and Garoff, H. (1991). A new generation of animal cell expression vectors based on the Semliki Forest virus replicons. Bio/Technology 9: 1356-1361.
13. Smerdou, C., and Liljeström, P. (1999). Two-helper RNA system for production of recombinant Semliki Forest virus particles. J. Virol. 73: 1092-1098.
14. Morris-Downes, M. M., et al (2002). Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. J. Neuroimmunol. 125: 114-124.
15. Morris-Downes, M. M., et al. (2002). Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) in ABH and SJL mice. J. Neuroimmunol. 122: 20-33.
16. Piccirillo, C. A., and Prudhomme, G. J. (1999). Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors. Hum. Gene Ther. 10: 1915-1922.
17. Furlan, R., et al. (2001). Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther. 8: 13-19.
18. Broberg, E., et al. (2001). Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther. 8: 769-777.
19. Cua, D. J., et al (2001). Central nervous system expression of IL-10 inhibits autoimmune encephalitis. J. Immunol. 166: 602-608.
20. Xiao, B. G., Bai, X. F., Zhang, G. X., and Link, H. (1998). Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J. Neuroimmunol. 84: 230-237.
21. Mokhtarian, F., and Swoveland, P. (1987). Predisposition to EAE induction in resistant mice by prior infection with Semliki Forest virus. J. Immunol. 138: 3264-3268.
22. Wu, L. X., et al. (1988). Effect of viral infection on experimental allergic encephalomyelitis in mice. J. Neuroimmunol. 18: 139-153.
23. Eralinna, J. P., et al. (1996). Blood-brain barrier breakdown and increased intercellular adhesion molecule (ICAM-1/CD54) expression after Semliki Forest (A7) virus infection facilitates the development of experimental allergic encephalomyelitis. J. Neuroimmunol. 66: 103-114.
24. Croxford, J. L., Feldmann, M., Chernajovsky, Y., and Baker, D. (2001). Different therapeutic outcomes in experimental allergic encephalomyelitis dependant upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J. Immunol. 166: 4124-4130.
25. Slavin, A. J., Maron, R., and Weiner, H. L. (2001). Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Intern. Immunol. 13: 825-833.
26. Miyaguchi, K., Maeda, Y., Collin, C., and Sihag, R. K. (2000). Gene transfer into hippocampal slice cultures with an adenovirus vector driven by cytomegalovirus promoter: stable co-expression of green fluorescent protein and lacZ genes. Brain Res. Bull. 51: 195-202.
27. Lundstrom, K., et al. (1999). Efficient in vivo expression of a reporter gene in rat brain after injection of recombinant replication-deficient Semliki Forest virus. Gene Ther. Mol. Biol. 3: 15-23.
28. Chun, S., et al. (1999). Distribution, fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10. J. Immunol. 163: 2393-2402.
29. Selmaj, K., et al. (2000). Naked DNA vaccination differentially modulates autoimmune responses in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 111: 34-44.
30. Tsunoda, I., et al (1999). Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol. 9: 481-493.
31. Rott, O., Fleischer, B., and Cash, E. (1994). Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24: 1434-1440.
32. Shaw, M. K., et al. (1997). Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J. Exp. Med. 185: 1711-1714.
33. Sandler, V. M., et al. (2002). Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. J. Neurosci. Methods 121: 211-219.
34. Fukuda, Y., et al (2003). Regulated transgene delivery by ganciclovir in the brain without physiological alterations by a live attenuated herpes simplex virus vector. Neurosci. Res. 45: 233-241.
35. Lilley, C. E., et al. (2001). Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J. Virol. 75: 4343-4356.
36. Klein, R. L., et al. (1998). Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 150: 183-194.
37. Klein, R. L., et al. (1999). Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience 90: 815-821.
38. Peel, A. L., et al. (1997). Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 4: 16-24.
39. Peel, A. L., and Klein, R. L. (2000). Adeno-associated virus vectors: activity and applications in the CNS. J. Neurosci. Methods 98: 95-104.
40. Lai, Z., and Brady, R. O. (2002). Gene transfer into the central nervous system in vivo using a recombinant lentivirus vector. J. Neurosci. Res. 67: 363-371.
41. Murphy, A. M., Morris-Downes, M. M., Sheahan, B. J., and Atkins, G. J. (2000). Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Ther. 7: 1477-1482.
42. Morris-Downes, M. M., et al. (1997). Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection. J. Neuroimmunol. 74: 185-197.
43. Sprinkle, T. J. (1989). 2′,3′-Cyclic nucleotide 3′-phosphodiesterase, an oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system. Crit. Rev. Neurobiol. 43: 235-301.
44. Huber, G., and Matus, A. (1984). Differences in the cellular distributions of two microtubule-associated proteins, MAP1 and MAP2, in rat brain. J. Neurosci. 4: 151-160.
45. Costa, O., et al. (2003). Optimization of an animal model of experimental autoimmune encephalomyelitis achieved with a multiple MOG(35-55) peptide in C57BL6/J strain of mice. J. Autoimmun. 20: 51-61.